参考文献/References:
[1] Katugampola SD, Maguire JJ, Matthewson SR, et al. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man [J]. Br J Pharmacol, 2001, 132(6): 1255-1260. doi:10.1038/sj.bjp.0703939.
[2] Tayebati SK, Lokhandwala MF, Amenta F. Dopamine and vascular dynamics control: present status and future perspectives [J]. Curr Neurovasc Res, 2011, 8(3): 246-257. doi:10.2174/156720211796558032.
[3] Goldberg LI. The pharmacological basis of the clinical use of dopamine [J]. Proc R Soc Med, 1977, 70 Suppl 2(Suppl 2): 7-15.
[4] Zhang MZ, Yao B, Fang X, et al. Intrarenal dopaminergic system regulates renin expression [J]. Hypertension, 2009, 53(3): 564-570. doi:10.1161/hypertensionaha.108.127035.
[5] White BH, Sidhu A. Increased oxidative stress in renal proximal tubules of the spontaneously hypertensive rat: a mechanism for defective dopamine D1A receptor/G-protein coupling [J]. J Hypertens, 1998, 16(11): 1659-1665. doi:10.1097/00004872-199816110-00013.
[6] Watanabe H, Xu J, Bengra C, et al. Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4 [J]. Kidney Int, 2002, 62(3): 790-798. doi:10.1046/j.1523-1755.2002.00525.x.
[7] Staessen JA, Kuznetsova T, Zhang H, et al. Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4 [J]. Hypertension, 2008, 51(6): 1643-1650. doi:10.1161/hypertensionaha.107.109611.
[8] Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension [J]. N Engl J Med, 2001, 345(21): 1548-1557. doi:10.1056/NEJMra010253.
[9] Ganguly PK, Mukherjee K, Sahai A. Renal dopamine receptors are involved in the development of cardiac hypertrophy [J]. Mol Cell Biochem, 1995, 144(1): 81-84. doi:10.1007/bf00926744.
[10] Hollon TR, Bek MJ, Lachowicz JE, et al. Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive [J]. J Neurosci, 2002, 22(24): 10801-10810. doi:10.1523/jneurosci.22-24-10801.2002.
[11] Massel D. Ibopamine and survival in severe congestive heart failure: PRIME II [J]. Lancet, 1997, 350(9071): 147. doi:10.1016/s0140-6736(05)61857-0.
[12] Yamaguchi T, Sumida TS, Nomura S, et al. Cardiac dopamine D1 receptor triggers ventricular arrhythmia in chronic heart failure [J]. Nat Commun, 2020, 11(1): 4364. doi:10.1038/s41467-020-18128-x.
[13] Li Z, Yu C, Han Y, et al. Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells [J]. Am J Physiol Heart Circ Physiol, 2008, 294(6): H2761-2768. doi:10.1152/ajpheart.01344.2007.
[14] Beazely MA, Watts VJ. Activation of a novel PKC isoform synergistically enhances D2L dopamine receptor-mediated sensitization of adenylate cyclase type 6 [J]. Cell Signal, 2005, 17(5): 647-653. doi:10.1016/j.cellsig.2004.10.003.
[15] Cho DI, Quan W, Oak MH, et al. Functional interaction between dopamine receptor subtypes for the regulation of c-fos expression [J]. Biochem Biophys Res Commun, 2007, 357(4): 1113-1118. doi:10.1016/j.bbrc.2007.04.066.
[16] Sarkis A, Lopez B, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension [J]. Curr Opin Nephrol Hypertens, 2004, 13(2): 205-214. doi:10.1097/00041552-200403000-00009.
[17] Li XX, Bek M, Asico LD, et al. Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice [J]. Hypertension, 2001, 38(3): 303-308. doi:10.1161/01.hyp.38.3.303.
[18] Thomas GN, Tomlinson B, Critchley JA. Modulation of blood pressure and obesity with the dopamine D2 receptor gene TaqI polymorphism [J]. Hypertension, 2000, 36(2): 177-182. doi:10.1161/01.hyp.36.2.177.
[19] Mejía-Rodríguez O, Alvarez-Aguilar C, Vega-Gómez HE, et al. Bromocriptine induces regression of left ventricular hypertrophy in peritoneal dialysis patients [J]. Proc West Pharmacol Soc, 2005, 48: 122-125.
[20] Li H, Shi S, Sun YH, et al. Dopamine D2 receptor stimulation inhibits angiotensin II-induced hypertrophy in cultured neonatal rat ventricular myocytes [J]. Clin Exp Pharmacol Physiol, 2009, 36(3): 312-318. doi:10.1111/j.1440-1681.2008.05064.x.
[21] Li HZ, Guo J, Gao J, et al. Role of dopamine D2 receptors in ischemia/reperfusion induced apoptosis of cultured neonatal rat cardiomyocytes [J]. J Biomed Sci, 2011, 18(1): 18. doi:10.1186/1423-0127-18-18.
[22] Wang S, Zhang F, Zhao G, et al. Mitochondrial PKC-ε deficiency promotes I/R-mediated myocardial injury via GSK3β-dependent mitochondrial permeability transition pore opening [J]. J Cell Mol Med, 2017, 21(9): 2009-2021. doi:10.1111/jcmm.13121.
[23] Han F, Konkalmatt P, Mokashi C, et al. Dopamine D(2) receptor modulates Wnt expression and control of cell proliferation [J]. Sci Rep, 2019, 9(1): 16861. doi:10.1038/s41598-019-52528-4.
[24] Zeng C, Wang D, Asico LD, et al. Aberrant D1 and D3 dopamine receptor transregulation in hypertension [J]. Hypertension, 2004, 43(3): 654-660. doi:10.1161/01.HYP.0000114601.30306.bf.
[25] Zeng C, Wang D, Yang Z, et al. Dopamine D1 receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles [J]. Hypertension, 2004, 43(3): 673-679. doi:10.1161/01.HYP.0000118958.27649.6f.
[26] Wang X, Villar VA, Armando I, et al. Dopamine, kidney, and hypertension: studies in dopamine receptor knockout mice [J]. Pediatr Nephrol, 2008, 23(12): 2131-2146. doi:10.1007/s00467-008-0901-3.
[27] Asico LD, Ladines C, Fuchs S, et al. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension [J]. J Clin Invest, 1998, 102(3): 493-498. doi:10.1172/jci3685.
[28] Johnson TL, Tulis DA, Keeler BE, et al. The dopamine D3 receptor knockout mouse mimics aging-related changes in autonomic function and cardiac fibrosis [J]. PLoS One, 2013, 8(8): e74116. doi:10.1371/journal.pone.0074116.
[29] Kisling A, Byrne S, Parekh RU, et al. Loss of Function in Dopamine D3 Receptor Attenuates Left Ventricular Cardiac Fibroblast Migration and Proliferation in vitro [J]. Front Cardiovasc Med, 2021, 8: 732282. doi:10.3389/fcvm.2021.732282.
[30] Sacks D, Baxter B, Campbell BCV, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke [J]. Int J Stroke, 2018, 13(6): 612-632. doi:10.1177/1747493018778713.
[31] Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension [J]. Hypertension, 1998, 32(2): 187-197. doi:10.1161/01.hyp.32.2.187.
[32] Bek MJ, Wang X, Asico LD, et al. Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice [J]. Hypertension, 2006, 47(2): 288-295. doi:10.1161/01.Hyp.0000198427.96225.36.
[33] Armando I, Villar VA, Jose PA. Dopamine and renal function and blood pressure regulation [J]. Compr Physiol, 2011, 1(3): 1075-1117. doi:10.1002/cphy.c100032.
[34] Sunahara RK, Guan HC, O’Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 [J]. Nature, 1991, 350(6319): 614-619. doi:10.1038/350614a0.
[35] Allayee H, de Bruin TW, Michelle Dominguez K, et al. Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p [J]. Hypertension, 2001, 38(4): 773-778. doi:10.1161/hy1001.092617.
[36] Cooper RS, Luke A, Zhu X, et al. Genome scan among Nigerians linking blood pressure to chromosomes 2, 3, and 19 [J]. Hypertension, 2002, 40(5): 629-633. doi:10.1161/01.hyp.0000035708.02789.39.
[37] Yang Z, Asico LD, Yu P, et al. D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure [J]. Am J Physiol Regul Integr Comp Physiol, 2006, 290(1): R96-r104. doi:10.1152/ajpregu.00434.2005.
[38] Lu Q, Yang Y, Villar VA, et al. D5 dopamine receptor decreases NADPH oxidase, reactive oxygen species and blood pressure via heme oxygenase-1 [J]. Hypertens Res, 2013, 36(8): 684-690. doi:10.1038/hr.2013.9.
[39] Banday AA, Lokhandwala MF. Transcription factor Nrf2 protects renal dopamine D1 receptor function during oxidative stress [J]. Hypertension, 2013, 62(3): 512-517. doi:10.1161/hypertensionaha.113.01358.
[40] Yang Z, Asico LD, Yu P, et al. D5 dopamine receptor regulation of phospholipase D [J]. Am J Physiol Heart Circ Physiol, 2005, 288(1): H55-61. doi:10.1152/ajpheart.00627.2004.
[41] Jiang X, Shao M, Liu X, et al. Reversible Treatment of Pressure Overload-Induced Left Ventricular Hypertrophy through Drd5 Nucleic Acid Delivery Mediated by Functional Polyaminoglycoside [J]. Adv Sci (Weinh), 2021, 8(5): 2003706. doi:10.1002/advs.202003706.
[42] Brogden RN,Markham A. Fenoldopam:a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies[J]. Drugs,1997,54(4):634-650.
[43] Ozono R, O’Connell DP, Vaughan C, et al. Expression of the subtype 1A dopamine receptor in the rat heart [J]. Hypertension, 1996, 27(3 Pt 2): 693-703. doi:10.1161/01.hyp.27.3.693.
[44] Sookhai S, Wang JH, Winter D, et al. Dopamine attenuates the chemoattractant effect of interleukin-8: a novel role in the systemic inflammatory response syndrome [J]. Shock, 2000, 14(3): 295-299. doi:10.1097/00024382-200014030-00009.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(8):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(8):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(8):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(8):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]